Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization
Activating the mevalonate (MVA) pathway increases bladder cancer (BLCA) spread. High MVA enzyme levels predict worse outcomes. Drugs like zoledronic acid or simvastatin blocking this pathway reduce cancer cell migration by affecting the protein RhoB. Targeting the MVA pathway could help treat BLCA.
Making multispecific capacity of antibodies into a precision medicine tool
Behind the scenes of our work to adapt an agonistic antibody with any type of drug cargo in order for us to improve the impact on the immune system and thereby therapeutic efficacy.
Beyond the Taste: A Multifunctional Gustatory Interface for Tongue Cancer Patients
Extensive surgical procedures involving flap reconstruction impact the taste perception for tongue cancer patients, highlighting the need for innovative approaches to dysgeusia.
Pectolinarigenin inhibits bladder urothelial carcinoma cell proliferation by regulating DNA damage/autophagy pathways
Pectolinarigenin (PEC) from herbal medicine targets DNA topoisomerase II alpha (TOP2A) in bladder cancer (BLCA), causing DNA damage and blocking cell division. It inhibits autophagy, boosting its effectiveness. Combined with gemcitabine, PEC more effectively halts BLCA growth.
Melatonin inhibits bladder tumorigenesis by suppressing PPARγ/ENO1-mediated glycolysis
Melatonin may help fight bladder cancer (BLCA) by slowing cancer cell energy production and increasing chemotherapy effectiveness, by targeting ENO1 to enhance gemcitabine’s impact and involving reactive oxygen species and PPARγ regulation. This suggests new methods for improving BLCA treatment.
Conditional reprogramming: Modeling urological cancer and translation to clinics
Patient-derived conditional reprogramming (CR) lets cells grow indefinitely, aiding in studying cancer, developing treatments, and advancing personalized medicine. This approach shows promise for improving urological cancer treatment.
Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway
Simvastatin, a drug for heart disease by lowering cholesterol, also slows bladder cancer (BLCA) growth. It stops BLCA cells from multiplying by activating PPARγ, a fatty aicd/lipid metabolism pathway. This effect can be reversed with PPARγ inhibitors.
MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3
Our research reveals that MYBL2, a gene-regulating protein, is elevated in bladder cancer (BLCA) and linked to worse patient outcomes. It boosts BLCA growth and spread by activating the CDCA3 gene, working with FOXM1 to enhance cancer traits. This identifies MYBL2 as a key promoter of BLCA.